Chemically Modified Oligomeric Compounds for miRNA Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for agents that can effectively regulate gene expression through mechanisms mediated by small non-coding RNAs, particularly microRNAs (miRNAs), which are involved in various physiological processes and are aberrantly expressed in disease states, but existing methods lack efficacy in modulating miRNA activity.
Innovation Solution
Chemically modified oligomeric compounds, specifically nucleic acid and nucleic acid-like oligomers, are designed to target and modulate miRNAs by hybridizing with or sterically interfering with nucleic acid molecules, utilizing a contiguous sequence of nucleosides with stabilizing modifications and internucleoside linking groups to enhance nuclease stability and binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically modified oligomeric compounds are designed with stabilizing modifications and internucleoside linking groups, then nuclease stability and binding affinity are enhanced, but device complexity increases
Solution Approach 1:
The oligomeric compound is divided into distinct segments: a central region containing at least 10 contiguous β-D-2′-deoxy-2′-fluororibofuranosyl nucleosides for miRNA binding, and terminal regions containing stabilizing modifications. This segmentation allows each region to perform its specific function independently while maintaining overall compound stability and efficacy.
Solution Approach 2:
The compound combines multiple nucleoside types with different properties: β-D-2′-deoxy-2′-fluororibofuranosyl nucleosides provide miRNA complementarity and binding affinity, while terminal stabilizing modifications (such as 2′-O-methoxyethyl or phosphorothioate linkages) provide nuclease resistance. This composite structure integrates different functional properties into a single therapeutic agent.
2Reliability
If oligomeric compounds are used to modulate miRNA activity, then gene expression regulation is achieved, but immunostimulatory activity may occur
Solution Approach 1:
The chemical parameters of the oligomeric compound are optimized to reduce immunostimulatory activity. Specifically, the use of β-D-2′-deoxy-2′-fluororibofuranosyl nucleosides with specific sugar pucker conformation and the incorporation of 2′-O-methoxyethyl modifications at terminal positions alter the compound's interaction with immune sensors, reducing unwanted immunostimulation while preserving miRNA modulation efficacy.
3Reliability
If existing methods are used to regulate gene expression via small non-coding RNAs, then some modulation capability is achieved, but efficacy is insufficient
Solution Approach 1:
The oligomeric compound acts as an intermediary molecule that bridges the gap between existing miRNA modulation approaches and desired therapeutic outcomes. The compound hybridizes with target miRNAs through complementary base pairing in its central region, while its modified structure enhances stability and reduces degradation, thereby improving therapeutic efficacy compared to unmodified antisense oligonucleotides.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These oligomeric compounds effectively modulate miRNA levels and activity, providing potent and improved therapeutic index, capable of inhibiting miRNA function and altering gene expression, particularly in disease-related miRNA states, with reduced immunostimulatory activity and enhanced stability.
Implementation Method 1
hybridize with or sterically interfere with nucleic acid molecules comprising or encoding small non-coding RNA targets
Implementation Method 2
sterically interfere with nucleic acid molecules
Data Source
AI summary
Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activating in a cell.